Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Jod S Mehta, ESCRS 2020 – Artificial Intelligence for Classification of Corneal Dystrophies Including Fuchs’ Endothelial Corneal Dystrophy (Part 2)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 3rd 2020

Prof. Jod S Mehta (Singapore National Eye Center, Singapore) kindly took time to speak to us about his presentation at ESCRS on artificial intelligence for classification of corneal dystrophies including Fuchs’ endothelial corneal dystrophy.

Questions

  1. Could you tell us a little about your recent study investigating automated guttae assessment for Fuchs’ endothelial corneal dystrophy? (0:08)
  2. What other techniques are emerging and what future studies are planned? (3:59)

Speaker Disclosure: Prof. Jod S Mehta has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of ESCRS 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup